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Added value of 68Ga-PSMA PET/CT for the
detection of bone metastases in patients
with newly diagnosed prostate cancer and
a previous 99mTc bone scintigraphy
Helle D. Zacho1,2* , Søren Ravn1, Ali Afshar-Oromieh3, Joan Fledelius4, June A. Ejlersen4 and Lars J. Petersen1,2
Abstract
Purpose: To investigate the added value and diagnostic accuracy of 68Ga-PSMA PET/CT versus bone scintigraphy
(BS) for bone metastasis detection at the primary staging of prostate cancer (PCa).
Methods: Inclusion criteria involved consecutive patients with newly diagnosed intermediate- to high-risk PCa, who
had undergone BS, mostly with supplementary SPECT/low-dose CT, and 68Ga-PSMA-11 PET/CT within less than 3
months without therapy initiation between the two investigations. BS was evaluated according to clinical routine
and reported as no bone metastases (M0), bone metastases (M1), or equivocal (Me). The 68Ga-PSMA-11 PET/CT was
blindly evaluated by three specialists as M0, M1, or Me at the patient level. Sensitivity analyses were conducted
using a “best valuable comparator” using all available imaging and clinical follow-up as a reference.
Results: In total, 112 patients were included; 68Ga-PSMA-11 PET/CT showed a sensitivity of 1.00, specificity of 0.93–
0.96, positive predictive value of 0.74–0.81, and negative predictive value of 1.00. 68Ga-PSMA-11 PET/CT revealed
bone metastases in 8 of 81 patients with M0 disease according to BS. 68Ga-PSMA-11 PET/CT confirmed the
presence of bone metastases in all patients (n = 9) with M1 disease according to BS. In patients with Me by BS,
68Ga-PSMA PET/CT provided a definite result in 20 of 22 patients. 68Ga-PSMA-11 PET/CT resulted in a false-positive
answer in four patients with solitary rib lesions.
Conclusion: 68Ga-PSMA-11 PET/CT revealed bone metastases in 10% of patients without bone metastases on BS
and in 36% patients with indeterminate BS. However, solitary PSMA-avid lesions in the ribs should be interpreted
cautiously as they may represent false-positive findings.
Keywords: PSMA PET/CT, Bone scintigraphy, Bone scan, Bone metastases, Newly diagnosed prostate cancer
Introduction
According to the European Association of Urology (EAU)
guidelines, bone scintigraphy (BS) is the recommended
imaging modality for the detection of bone metastases in
patients with newly diagnosed unfavorable intermediate-
to high-risk prostate cancer (PCa) [1]. The presence of
bone metastases as well as the number of bone metastases
are of great significance to tailor the treatment [1–3] and
to determine patients’ prognosis [4].
Positron emission tomography/computed tomography
with ligands of the prostate-specific membrane antigen
(PSMA PET/CT), especially with the 68Ga-labelled ligand
PSMA-11, has been used widely to assess PCa metastases,
particularly at the time of biochemical recurrence [5, 6],
but 68Ga-PSMA PET/CT has also been shown to possess
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premium diagnostic accuracy for the detection of bone
metastases at the time of primary staging [7, 8].
The purpose of this study was twofold. First, we aimed
to evaluate the added value of 68Ga-PSMA-11 PET/CT
in patients with newly diagnosed PCa versus the value of
the initial BS and to assess the diagnostic accuracy of
68Ga-PSMA-11 PET/CT for skeletal metastasis patients
with PCa at the time of primary staging.
Materials and methods
Patients
From May 2015 to October 2018, all patients undergo-
ing PSMA PET/CT at our department were screened for
inclusion in the present retrospective study. The eligibil-
ity criteria were as follows: (1) newly diagnosed with
PCa, (2) no prior treatment for PCa, (3) 99mTc BS per-
formed within 3 months of the 68Ga-PSMA-11 PET/CT,
and (4) no treatment for PCa initiated between BS and
PSMA PET/CT. All patients had BS and a CT scan of
the thorax, abdomen, and pelvis conducted as part of
the routine staging procedure according to the recom-
mendations of the EAU [1].
68PSMA-PET/CT
In short, the 68Ga-PSMA-11 ligand was used in the
present study and was synthesized as previously described
[9]. The 68Ga-PSMA-11 PET/CT was performed in ac-
cordance with the guidelines of the European Association
of Nuclear Medicine/Society of Nuclear Medicine
(EANM) on 68Ga-PSMA-11 PET/CT [10]. Images were
acquired approximately 60 min after an intravenous injec-
tion of 2 MBq/kg body weight (minimum 100 MBq, max-
imum 200 MBq). Patients were examined using either a
VCT Discovery True 64 PET/CT system (GE Healthcare,
USA) or a Siemens Biograph mCT Flow 64 PET/CT sys-
tem (Siemens, Erlangen Germany). The patients were
scanned from the base of the skull to the upper thigh, and
the PET images were acquired in 3D mode. The PET im-
ages were reconstructed using attenuation correction
using an ordered subset expectation-maximization algo-
rithm. For the Siemens Biograph, mCT Flow 64 PET/CT
time-of-flight and point-spread-function were applied. A
low-dose CT was performed immediately after the PET
scan and used for attenuation correction and anatomical
co-registration.
99mTc bone scintigraphy
BS was conducted in accordance with the EANM guide-
lines for BS [11]. A planar whole body BS scan was ac-
quired on a two-headed gamma camera (Symbia T16,
Siemens Medical Solutions, Erlangen, Germany) 2–3 h
after the intravenous injection of 9.4 MBq 99mTc-labelled
methylene bisphosphonate per kilogram body weight
(minimum 750 MBq). A supplemental single-photon
emission computed tomography (SPECT)/CT, covering
one- or two-bed positions (each 40 cm field of view),
was conducted at the discretion of the physician in
charge. SPECT/CT was acquired using the following pa-
rameters: 16 views with 10 s per view, as previously de-
scribed [12]. The images were reconstructed using
iterative reconstruction with scatter correction. A low-
dose CT was performed for attenuation correction and
anatomical co-registration. Planar bone scan and any
supplementary SPECT/low-dose CT was considered the
standard bone evaluation per clinical guideline recom-
mendation. According to institutional practice, a
contrast-enhanced CT was performed after the bone
scan for the assessment of lymph node and soft tissue
metastasis. The information from the “bone window”
was not included in the comparison with PSMA PET. In
retrospect, no patients had any findings in the contrast-
enhanced bone window, which changes the overall BS
classification of metastasis.
Observers and procedure for image assessment
The evaluation of BS was a part of the daily clinical
practice. The BS results were evaluated by at least two
observers, mostly one physician in training and re-read
by at least one experienced board-certified specialist in
nuclear medicine. The consensus result was categorized
as either (1) no bone metastases, (2) equivocal for bone
metastases in which case it was an institutional practice
to conduct a 68Ga-PSMA-11 for confirming or ruling
out bone metastases, or (3) bone metastases.
The 68Ga-PSMA-11 PET/CT images were evaluated
by three board-certified nuclear medicine physicians
with experience in the evaluation of 68Ga-PSMA-11
PET/CT [13]. The evaluation of 68Ga-PSMA-11 PET/CT
was conducted according to Rauscher et al. [14]. The
PSMA PET/CT images were categorized on a three-
point-scale: bone metastases (M1), no bone metastases
(M0), or equivocal in patients with bone lesions not typ-
ical for bone metastases (Me). Furthermore, the exact
number and location of all equivocal or metastatic bone
lesions were described in patients with 10 or fewer le-
sions. The observers had no access to any clinical infor-
mation except that the patients were newly diagnosed
with prostate cancer and were instructed to evaluate the
PSMA PET using the corresponding CT-images as they
would do in their daily clinical practice. Likewise, the
observers were blinded to the evaluation of the BS. Cases
of disagreement were resolved by consensus.
Best valuable comparator
In most cases, a histopathologic reference standard was
not available for ethical and practical reasons. For the
present study, we defined a “best valuable comparator”
(BVC) for the presence or absence of bone metastases at
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the patient level similar to previous diagnostic studies of
bone metastases [6, 8, 15]. The BVC was based on all
available imaging results available at the time of staging
as well as supplementary and/or follow-up imaging (all
modalities). A minimum of 12 months of clinical and
laboratory follow-up was required. Patients with PSA <
0.1 ng/mL after radical prostatectomy without any sys-
temic treatment were categorized as having no bone
metastases at the time of staging [16].
Statistics
Diagnostic accuracy was calculated among patients with
a valid BVC. Sensitivity analyses were performed for
each component of the diagnostic accuracy endpoints
(sensitivity, specificity, positive, and negative predictive
values), where patients with equivocal findings were first
considered positive for metastases (pessimistic analyses)
and then calculated as negative for metastases (optimis-
tic analysis). The results are summarized by the mean or
median values, standard deviations and ranges. Statistical
analyses were performed using STATA®11 (StataCorp
LP, College Station, TX, USA). All results are reported
with 95% confidence intervals (CIs).
Ethics
Due to the retrospective nature of the study, no formal
approval from the ethics committee was required ac-
cording to our national legislation. The study was ap-
proved by the Danish Data Protection Agency (approval
number 2008-58-0028).
Results
Patients
One hundred eighteen consecutive patients underwent
68Ga-PSMA-11 PET/CT at the time of initial staging,
and of these patients, 6 did not undergo BS within 3
months of the 68Ga-PSMA-11 PET/CT. Thus, 112 pa-
tients were included in the analysis. The great majority
(n = 99, 88%) of the patients had high-risk disease ac-
cording to the EAU criteria (Table 1). Twenty-two pa-
tients (20%) were referred for a 68Ga-PSMA-11 PET/CT
solely due to equivocal results from initial staging BS,
and 30 patients were referred due to equivocal lesions
identified by CT (Table 1). The initial BS showed no me-
tastases in 81 patients (72%), equivocal results in 22 pa-
tients (20%), and bone metastases in 9 patients (8%). BS
was conducted prior to 68Ga-PSMA-11 PET/CT in all
patients. A BVC at the patient level was available in 105
of 112 (94%) patients with a median follow-up time of
21 months (range 12–50 months). In seven patients, no
firm conclusion regarding the presence or absence of
bone metastases was achievable. This result was mainly
due to patients undergoing androgen-deprivation ther-
apy (ADT) without any follow-up imaging.
68Ga-PSMA-11 PET/CT in patients classified as M0 by BS
In patients without bone metastases based on BS (n = 81),
68Ga-PSMA-11 PET/CT showed metastasis-suspicious le-
sions in eight patients (10%) (Fig. 1) and equivocal results
in two patients (2%). 68Ga-PSMA-11 PET/CT was nega-
tive for bone metastasis in 71 patients (88%). Among the
eight patients with suspected bone metastases exclusively
shown by 68Ga-PSMA-11 PET/CT, six had skeletal metas-
tases confirmed by the BVC, whereas two patients had
false-positive lesions (Fig. 2, Supplementary Table 1); both
patients had PSMA-avid uptake in the ribs only. Two pa-
tients with equivocal findings by 68Ga-PSMA-11 PET/CT
also presented with solitary PSMA uptake in the ribs, a
BVC could not be established in both patients as they
Table 1 Demographic data
Patient demographics (n = 112)
Age (years), mean (range) 68 (48–78)
PSA (ng/mL), mean (range) 34.5 (1.7–
276)
median 21
Gleason
7 (3 + 4), n 17 (15.2%)
7 (4 + 3), n 24 (21.4%)
8, n 10 (8.9%)
9, n 61 (54.5%)
T-stage
T1, n 24 (21.4%)
T2, n 37 (33.0%)
T3, n 47 (42.0%)
T4, n 4 (3.6%)
EAU risk score
Favorable* intermediate, n 7 (6.3%)
Unfavorable intermediate risk, n 6 (5.4%)
High risk, n 99 (88.4%)
Reason for PSMA-PET/CT
CT equivocal 30 (26.8%)
Bone scan equivocal 22 (19.6%)
Very high risk and no metastases according to BS or
CT
28 (25.0%)
Participation in a PSMA-study 20 (17.9%)
Miscellaneous 12 (10.7%)
Bone scintigraphy prior to inclusion
Planar whole body 23 (20.5%)
Planar whole body + SPECT/CT 89 (79.5%)
Time between PSMA-PET/CT and BS (days)
Median (range) 22 (6–80)
BS bone scintigraphy, CT computed tomography, EAU European Association of
Urology, SPECT single-photon emission computed tomography
*Intermediate EAU risk differentiate between patients with Gleason 7 (3+4) as
favorable and Gleason 7 (4 + 3) as unfavorable
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were referred for ADT and did not undergo follow-up im-
aging. 68Ga-PSMA-11 PET/CT did not show any false-
negative cases among patients with a negative or equivocal
68Ga-PSMA-11 PET/CT.
68Ga-PSMA-11 PET/CT in patients with equivocal lesions
on BS
In patients referred to 68Ga-PSMA-11 PET/CT due to
equivocal lesions on BS (n = 22), 68Ga-PSMA-11 PET/
CT provided a definitive diagnosis of bone metastases in
20 of 22 patients. PSMA-avid lesions suspicious for bone
metastases were found in 9 patients (41%), 68Ga-PSMA-
11 PET/CT was equivocal in 2 patients, and it was nega-
tive in 11 (50%) patients. Compared to the BVC, two of
nine patients with PSMA-avid bone lesions had false-
positive results based on 68Ga-PSMA-11 PET/CT (Sup-
plementary Table 1). In both patients, the false-positive
lesions were located in the ribs (Fig. 3).
68Ga-PSMA-11 PET/CT in patients classified as M1 by BS
In all nine patients with bone metastases according to
BS, 68Ga-PSMA-11 PET/CT also showed PSMA-avid le-
sions suspicious of bone metastases. All patients were
true positive for skeletal metastases according to the
BVC. In one patient with three bone metastases accord-
ing to the BS, 68Ga-PSMA-11 PET/CT revealed more
than 10 lesions (Fig. 4). In three patients, 68Ga-PSMA-11
PET/CT increased the number of bone lesions identified
from 4 to 5, 8, and 9. In the remaining five patients, the
number and location of lesions identified by BS and
68Ga-PSMA-11 PET/CT were identical.
Diagnostic accuracy of 68Ga-PSMA-11 PET/CT
Overall, the sensitivity of 68Ga-PSMA-11 PET/CT for the
detection of bone metastases was excellent, with no false-
negative patients (sensitivity 100%). The specificity ranged
from 0.93 to 0.96, depending on whether equivocal find-
ings were considered M0 or M1 per BVC (Table 2). Four
patients had false-positive bone metastases according to
68Ga-PSMA-11 PET/CT, and one patient had equivocal
lesions based on 68Ga-PSMA-11 PET/CT, which were be-
nign according to the BVC. In all cases of false-positive le-
sions, the PSMA-avid lesions were located in the ribs and
exhibited slight sclerotic, though unspecific, changes based
on CT. Moreover, none of the patients with false-positive
bone lesions had other PSMA-avid lesions, except for
PSMA uptake in the prostate. One patient had a biopsy of
the rib lesion (which was benign), and three patients
underwent radical prostatectomy without any systemic
treatment and their PSA levels remained below 0.1 ng/mL
during follow-up for at least 12 months (Supplementary
Table 1). A total of seven patients exhibited solitary PSMA
uptake in rib lesions. The BVC did not declare any of
these lesions as bone metastases; the BVC was M0 in five
patients and a firm diagnosis of bone metastases could not
be obtained in two of the patients. Thus, there was no
cases of true positive solitary rib lesions on PSMA PET.
a b c
d
e
Fig. 1 Example of a patient (PSA 44 ng/mL, Gleason score 9, T3) classified as M0 according to initial BS as shown in anterior (a) and posterior
projection (b). The patient was referred for 68Ga-PSMA-11 PET/CT due to high-risk prostate cancer. The maximum intensity projection (MIP) of the
68Ga-PSMA-11 PET (c) revealed several lesions with avid 68Ga-PSMA-11 uptake, including three bone metastases marked with arrows (Th8, left iliac
bone and right pubic bone). The axial 68Ga-PSMA-11 PET image of the lesion in Th8 is shown in c with a fused 68Ga-PSMA-11 PET/CT image
shown in d and only a slight sclerotic change in the axial CT image (e). BVC confirmed M1 status
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Discussion
The present study investigated the added value of 68Ga-
PSMA-11 PET/CT in patients with newly diagnosed
PCa who recently underwent BS. 68Ga-PSMA-11 PET/
CT diagnosed bone metastases in 10% of patients with
negative BS results, provided a firm diagnosis in 20 of 22
patients referred for 68Ga-PSMA-11 PET/CT due to
equivocal BS results, and confirmed bone metastatic dis-
ease in all patients with positive BS results, but 68Ga-
PSMA-11 PET/CT also identified a notable proportion
of patients in whom PSMA-avid lesions in the ribs were
false positive.
Pyka et al. published the first comparison of 68Ga-
PSMA-11 PET/CT with BS in patients with PCa, includ-
ing 37 patients at primary staging [8]. They found a sen-
sitivity and specificity of 68Ga-PSMA-11 PET/CT of
100% at primary staging. Likewise, Lengana et al. re-
ported a sensitivity of 96% and specificity of 100% of
68Ga-PSMA PET/CT for the detection of bone metasta-
ses at primary staging [7]. In the present study, the sen-
sitivity was comparable to that found in prior studies,
whereas the specificity was slightly lower than the previ-
ously reported specificity, which might be explained by
the four patients with false-positive PSMA-avid uptake
in the ribs.
68Ga-PSMA-11 PET/CT has previously shown an abil-
ity to detect bone metastases in a proportion of patients
without bone metastases apparent on BS. Lengana et al.
reported that PSMA PET/CT revealed bone metastases
in 8.4% of patients with negative BS results [7], which is
in line with the present findings in which 10% of the pa-
tients without bone metastases on BS were considered
metastatic by PSMA. Among patients with bone metas-
tases on BS, PSMA PET/CT confirmed M1 bone disease
in all patients and showed more metastasis-suspected le-
sions than those detected by BS. These findings are in
line with recent observations [7].
Although PSMA PET/CT was indeterminate in some
cases, it provided a definitive imaging diagnosis among
96.4% of the patients in this population at the primary
staging. These findings are comparable to findings in pa-
tients with biochemical recurrence after curatively
intended treatment, where PSMA has been shown to
provide a definite diagnosis in 99% of patients [17].
The fact that four patients obtained false-positive re-
sults based on PSMA PET/CT was unexpected and has
a b c f
d g
e h
Fig. 2 Example of a patient (PSA 13, Gleason score 9, T2b) with no bone metastases according to BS (shown in anterior projection) (a) but with
two suspicious lesions in the seventh right rib and the eighth left rib according to the 68Ga-PSMA-11 PET/CT. Except for the 68Ga-PSMA-11 uptake
in the ribs and the prostate, no other suspicious lesions were observed. The 68Ga-PSMA-11 PET MIP showed two rib lesions (b); the full arrow
indicates a bone lesion in the seventh rib on the right side with corresponding axial 68Ga-PSMA-11 PET (c), 68Ga-PSMA-11 PET/CT fusion (d) and
CT (e). The hatched arrow indicates a bone lesion in the left eighth rib with corresponding axial PSMA PET and corresponding axial 68Ga-PSMA-
11 PET (f), 68Ga-PSMA-11 PET/CT fusion (g), and CT (h). The patient had no bone metastases according to the BVC: the patient had a radical
prostatectomy without any systemic treatment, and the post-prostatectomy PSA level was < 0.1 ng/mL and remained so until this study
was published
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not been reported in prior studies [8, 17]. In each of
these four patients presenting with a total of five PSMA-
avid lesions of non-prostatic origin, morphologic
changes were observed in the corresponding CT images.
However, biopsy ruled out bone metastases in one pa-
tient. In addition, the incorporation of a PSA < 0.1 ng/
mL 12 months after radical prostatectomy served as a
relatively reliable verification of non-metastatic diseases
in three patients. In accordance with the BVC, PSA-
negative metastatic PCa in the mentioned patients is
very unlikely. The false-positive findings were likely not
due to reader inexperience; two of the observers (HDZ
and AAO) were highly experienced and evaluated PSMA
PET/CT in numerous trials [5, 6, 17]. After we per-
formed the blinded evaluation of the 68Ga-PSMA-11
PET/CT in the present study, a number of cases with
PSMA-avid bone uptake in benign skeletal conditions
were published [18–21], revealing that fibrous dysplasia
in the ribs or rib fractures may be PSMA-avid. In sum-
mary, these findings emphasize the need for careful in-
terpretation of PSMA PET/CT in rib lesions.
The strength of the present study is the consecutive
inclusion of patients. Due to the unique national security
number in Denmark, it was possible to perform a
thorough follow-up on patients included in the study,
even if the patients moved across regions within the
country. In the present study, detailed follow-up data
were available in most patients. A shortcoming is that
histologic confirmation is rarely available in imaging
studies of the bone. However, performing biopsy rou-
tinely is not ethically reasonable, and consequently, a
composite endpoint (BVC) was applied in the present
study. A BVC has previously been used in diagnostic
studies of bone metastases, including studies comparing
68Ga-PSMA-11 PET/CT to BS [6–8, 15]. One of the lim-
itations of the BVC is that the index test itself often
plays a key role in the definition of the BVC, as the in-
terpretation of a new and promising method might be
unreasonably trusted in the final conclusion based on
the BVC. In addition, the extent of clinical, imaging, and
biochemical data available for the BVC have seldom
been reported. Here, we included detailed information
for a minimum of 12 months for all patients with at least
one lesion according to either BS or PSMA. A minority
of patients did not have data allowing for a definitive
conclusion of BVC. For these reasons, it is imperative to
consider the intrinsic verification bias when using a
BVC. For the present study, the limitations are reflected
a b c
d
e
Fig. 3 Example of a patient (PSA 6 ng/mL, Gleason score 7, T2b) with four equivocal lesions according to BS (shown in anterior projection) (a)
including a lesion in the fourth right rib indicated by the arrow. According to the 68Ga-PSMA-11 PET/CT, the lesion was considered metastatic as
shown by the 68Ga-PSMA-11 MIP (b) with the corresponding axial 68Ga-PSMA-11 PET (c), PET/CT fusion (d), and a slight sclerotic lesion in the axial
CT image (e). Except for the high 68Ga-PSMA-11 uptake in the prostate, no other suspicious lesions were observed. The patient underwent a CT-
guided biopsy that showed benign findings, and then the patient had a radical prostatectomy without any systemic treatment. The PSA dropped
to < 0.1 ng/mL after prostatectomy and remained so for at least 12 months
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in the sensitivity of 1.00, which is likely to be
overestimated.
Patients were excluded if they had received any kind
of treatment for PCa prior to BS and 68Ga-PSMA-11
PET/CT, which indicates that the scans were not influ-
enced by the negative effects of ADT on PSMA PET/CT
as described previously [22].
Despite the consecutive inclusion of patients, the present
population was biased because more than 20% of the pa-
tients were referred to 68Ga-PSMA-11 PET/CT due to
equivocal findings in BS. The study was not a head-to-head
comparative diagnostic test accuracy study. Therefore, no
comparative analysis of diagnostic accuracy for the detection
of bone metastases by BS was conducted. Likewise, the high
proportion of patients with equivocal BS does not reflect the
true frequency of equivocal findings in BS when SPECT/CT
is applied, which in unselected populations has been shown
to be approximately 10% at the time of initial staging [23]. In
the present setting, approximately 80% of the patients had a
SPECT/CT performed as an add-on to the planar bone scin-
tigraphy which is a limitation of the study. However, the use
of SPECT/CT in patients with planar BS with possible be-
nign or equivocal lesions reflects everyday clinical practice at
our institution, where patients with a normal bone scintig-
raphy or harboring several obvious malignant lesions are not
succumbed to additional SPECT/CT.
a b
Fig. 4 Example of a patient (PSA 8 ng/mL, Gleason score 9, T3) with three bone metastases (shown by the arrows) on BS (shown in posterior
projection) (a), whereas the 68Ga-PSMA-11 PET/CT revealed numerous bone lesions and lymph nodes in the pelvis and abdomen. The MIP of the
68Ga-PSMA-11 PET/CT is shown in anterior projection (b), and the arrows indicate the bone metastases also shown by BS
Table 2 Diagnostic accuracy of 68Ga-PSMA PET/CT among 105 patients with a final diagnosis (BVC) for the presence or absence of
bone metastases
M0 by BVC,
n = 88
M1 by BVC,
n = 17
M0 Equivocal M1 M0 Equivocal M1 Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
Three-point scale by three observers 82 2 4 0 0 17 – – – –
Optimistic analysis: Equivocal result
considered M0
84 4 0 17 1.00 (0.81–
1.00)
0.96 (0.89–
0.99)
0.81 (0.58–0.95) 1.00 (0.96–1.00)
Pessimistic analysis: equivocal result
considered M1
82 6 0 17 1.00 (0.81–
1.00)
0.93 (0.86–
0.98)
0.74 (0.52–0.90) 1.00 (0.96–1.00)
BVC best valuable comparator, CI confidence interval, M0 no bone metastases, Equivocal findings are equivocal for bone metastases, M1 bone metastases present,
PPV positive predictive value, NPV negative predictive value
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Conclusion
68Ga-PSMA-11 PET/CT exhibited few equivocal bone
findings and revealed bone metastases in 10% of patients
with newly diagnosed PCa and negative BS results. How-
ever, PSMA-avid lesions in the ribs without other PSMA-
avid lesions outside the prostate should be interpreted
cautiously as they often represent non-prostatic tissue.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13550-020-00618-0.
Additional file 1: Table S1. Best valuable comparator for bone
metastases in 41 patients with at least one positive lesion demonstrated
by any of the imaging modalities (BS or PSMA PET/CT).
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